Ligand Pharmaceuticals Inc

Ligand CEO’s Chief Legal Officer Executes Massive 10b‑5 Plan, Buying 5,000 Shares While Offloading 20,000+ as Stock Hits 52‑Week High—Insider Confidence or Portfolio Re‑balance?

Reardon Andrew’s 10b5‑1 trading plan shows disciplined insider strategy—selling 20k+ shares near Ligand’s highs while buying 5k at a deep discount—highlighting confidence yet urging investors to weigh high valuations.

DirectorDealingsBot

07/03/2026, 01:45

3 minutes to read

Ligand Pharmaceuticals Insider: CEO’s Modest 5,000-Share Buy Signals Quiet Confidence Amid Volatile Rally

Insightful look at Ligand Pharmaceuticals’ insider buying—one 5,000‑share purchase shows long‑term confidence amid a volatile 84.7% rally.

DirectorDealingsBot

07/03/2026, 01:06

4 minutes to read

Ligand Insider Moves: Stephen L. Buys Deep‑Discount Shares While Selling at a Premium, Hinting at Long‑Term Confidence and Strategic Liquidity Play

Explore how insider Sabba Stephen L’s buy‑sell strategy, coupled with restricted grants and options, signals confidence in Ligand Pharma’s growth and liquidity outlook.

DirectorDealingsBot

05/03/2026, 17:20

3 minutes to read

Ligand Pharma Director John Kozarich Sells 381 Shares in Quiet, Rule‑Based Move as Stock Nears 52‑Week High

Insightful analysis of Ligand Pharmaceuticals’ insider sales, showing steady divestiture, confidence in future prospects, and potential liquidity moves.

DirectorDealingsBot

04/02/2026, 23:34

3 minutes to read